INVO Fertility (NASDAQ:IVF) Announces Earnings Results

INVO Fertility (NASDAQ:IVF) posted its earnings results on Friday. The company reported $0.35 earnings per share for the quarter, Zacks reports. The company had revenue of $2.18 million during the quarter. INVO Fertility had a negative return on equity of 420.62% and a negative net margin of 183.75%.

INVO Fertility Stock Up 0.2%

NASDAQ:IVF traded up $0.00 during mid-day trading on Friday, hitting $0.97. 48,505 shares of the company’s stock traded hands, compared to its average volume of 78,813. The company has a fifty day moving average of $1.27 and a 200 day moving average of $2.61. INVO Fertility has a twelve month low of $0.90 and a twelve month high of $84.40. The company has a market capitalization of $2.23 million, a P/E ratio of -0.00 and a beta of 2.32. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.87 and a current ratio of 0.90.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of INVO Fertility in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Institutional Investors Weigh In On INVO Fertility

An institutional investor recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC purchased a new position in shares of INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.